L M Vance
Overview
Explore the profile of L M Vance including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vance L, Malcolm S, Hsiung H, Smith D, Heinz B
Arch Virol
. 1999 Sep;
144(8):1569-85.
PMID: 10486111
Enviroxime and related analogs are potent inhibitors of rhinoviruses and enteroviruses in cell culture. Previous analyses of resistant mutants implicated the viral nonstructural protein 3A(B) as the likely target of...
2.
Vance L, Moscufo N, Chow M, Heinz B
J Virol
. 1997 Oct;
71(11):8759-65.
PMID: 9343235
We have been exploring the mechanism of action of 5-(3,4-dichlorophenyl) methylhydantoin (hydantoin), an antiviral drug that inhibits the replication of poliovirus in culture. By varying the time of drug addition...
3.
Victor F, Brown T, Campanale K, Heinz B, Shipley L, Su K, et al.
J Med Chem
. 1997 May;
40(10):1511-8.
PMID: 9154972
A series of vinylacetylene analogs of Enviroxime (1) was synthesized. The new compounds are potent inhibitors of poliovirus in tissue culture. Cross-sensitivity with Enviroxime-derived mutants shows that the new compounds...
4.
Heinz B, Vance L
J Virol
. 1996 Jul;
70(7):4854-7.
PMID: 8676522
Using site-directed mutagenesis of the 3A coding region of rhinovirus 14, we have expanded our analysis of resistance to enviroxime. We have observed that high and low levels of drug...
5.
Heinz B, Vance L
J Virol
. 1995 Jul;
69(7):4189-97.
PMID: 7769678
Enviroxime is an antiviral compound that inhibits the replication of rhinoviruses and enteroviruses. We have explored the mechanism of action of enviroxime by using poliovirus type 1 and human rhinovirus...